Cladribine (Mavenclad): What It Is, How It Works, and What to Expect

What Is Cladribine (Mavenclad)?

Cladribine, sold under the brand name Mavenclad, is a prescription medication used to treat relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS and active secondary progressive MS. It belongs to a class of drugs known as purine nucleoside analogues and works by selectively targeting and depleting certain immune cells that drive the inflammatory damage seen in MS. Unlike many other disease-modifying therapies that require frequent dosing, cladribine is given as short courses of tablets, which makes it a distinctive option in the MS treatment landscape.

How Cladribine Works

Cladribine interferes with DNA synthesis in rapidly dividing cells, particularly lymphocytes. It preferentially accumulates in T and B cells, leading to their temporary reduction. By lowering the number of these overactive immune cells, cladribine reduces the inflammation and demyelination that cause MS relapses and lesion formation. The drug is then gradually cleared from the body, allowing the immune system to reconstitute itself in a more balanced state.

Dosing and Treatment Schedule

Cladribine is taken as oral tablets in two short treatment courses per year, usually spaced about one month apart. Each course lasts four to five consecutive days. The total cumulative dose over a full treatment year is typically 3.5 mg per kilogram of body weight. Many patients complete two full treatment years, after which no further treatment is usually needed, though a physician may recommend additional courses based on disease activity and individual response.

• First treatment year: two courses, one month apart.
• Second treatment year: two courses, one month apart.
• Cumulative dose: 3.5 mg/kg total per year.
• Tablets are taken orally, with or without food.

Eligibility and Who Should Consider It

Cladribine is generally considered for adults with relapsing forms of MS who have had active disease despite prior treatment or who are looking for a time-limited therapy. It may be especially appealing for patients who prefer not to commit to long-term daily or monthly injections or infusions. A physician will evaluate factors such as disease activity, prior treatment history, baseline blood counts, and overall health before recommending cladribine.

Side Effects and Safety Considerations

Because cladribine temporarily reduces lymphocyte counts, the most common risks involve infection and changes in blood parameters. The most frequently reported side effects include upper respiratory tract infections, headache, and herpes virus infections such as cold sores or shingles. Some patients experience a temporary drop in white blood cell counts, which is why regular blood monitoring is required before and during treatment.

Serious Risks to Discuss with a Doctor

• Increased risk of infections, including serious or opportunistic infections.
• Potential for herpes zoster (shingles), which may be prevented with vaccination before starting treatment.
• Changes in blood cell counts, including lymphopenia and neutropenia.
• Rare reports of progressive multifocal leukoencephalopathy (PML), though this is very uncommon.
• Liver enzyme elevations and, in rare cases, liver injury.

Monitoring and Lab Requirements

Before starting cladribine, patients need a complete blood count and liver function tests. During treatment, blood tests are repeated at regular intervals to ensure lymphocyte counts remain within acceptable ranges. If counts drop too low, treatment may be delayed or the dose adjusted. After completing the treatment courses, ongoing monitoring is still recommended to track immune reconstitution and long-term safety.

Comparing Cladribine to Other MS Treatments

Cladribine differs from many other MS therapies in its time-limited schedule. While drugs like ocrelizumab, natalizumab, or fingolimod require ongoing infusions, injections, or daily pills, cladribine is given in short pulses. This can reduce the burden of long-term immunosuppression, but it also means that patients need careful selection, as the drug's effects are concentrated rather than spread continuously. The choice between cladribine and other therapies depends on disease severity, lifestyle factors, and a patient's tolerance for different risk profiles.

Practical Considerations for Patients

Patients starting cladribine should plan for regular lab visits and discuss vaccination status with their healthcare team, particularly for herpes zoster. Because the drug can affect blood counts, any signs of infection such as fever, persistent sore throat, or unusual bruising should be reported promptly. Keeping a record of symptoms, lab results, and any side effects between appointments helps clinicians make informed decisions about dose adjustments or future treatment plans.

Conclusion

Cladribine (Mavenclad) offers a time-limited, oral treatment option for relapsing MS that can reduce disease activity without the need for indefinite therapy. Its distinctive pulsed dosing schedule sets it apart from other disease-modifying treatments, but it requires careful patient selection, blood monitoring, and awareness of potential infection risks. Anyone considering cladribine should discuss their full medical history and treatment goals with an MS specialist to determine whether it is the right fit.